{{Rsnum
|rsid=2650427
|Gene=GRIN2A
|Chromosome=16
|position=10020701
|Orientation=plus
|GMAF=0.4605
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GRIN2A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 33.8 | 49.2 | 16.9
| HCB | 13.3 | 60.0 | 26.7
| JPT | 22.2 | 33.3 | 44.4
| YRI | 27.0 | 42.9 | 30.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 60.0 | 26.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{omim
|desc=HUNTINGTON DISEASE; HD
|id=143100
|rsnum=2650427
}}

{{PMID Auto
|PMID=17569088
|Title=NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner.
}}

{{PMID Auto
|PMID=23644918
|Title=Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}